Syndax Pharmaceuticals, Inc. last reported quarterly results on Nov 2, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $83.3 million (+81.6% year over year) and diluted EPS of -$0.55. It usually reports 12–35 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–35 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 2, 2026
33 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
83
+81.6%
|
-49
+18.6%
|
-0.55
+21.4%
|
|
Aug 4, 2026
35 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
73
+91.8%
|
-49
+31.3%
|
-0.55
+33.7%
|
|
Apr 30, 2026
30 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
65
+223.6%
|
-43
+49.7%
|
-0.48
+51.0%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
69
+794.9%
|
-68
+27.8%
|
-0.78
+28.1%
|
|
Nov 3, 2025
34 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
46
+267.0%
|
-61
+27.8%
|
-0.70
+28.6%
|
|
Aug 4, 2025
35 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
38
+984.5%
|
-72
-5.6%
|
-0.83
-3.7%
|
|
May 5, 2025
35 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
20
|
-85
-17.2%
|
-0.98
-15.3%
|
|
Mar 3, 2025
62 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
8
|
-94
-29.9%
|
-1.09
-8.9%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SNDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1395937
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.